Testing a new drug alone and with pembrolizumab for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called JZP898, given alone or with pembrolizumab, for adults with advanced solid tumors that have stopped responding to other treatments. It aims to see if this combination can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced or metastatic solid tumor that has been confirmed by a biopsy or similar test.
- For certain tumors (like lung, melanoma, head and neck, kidney, liver, stomach, bladder, or colorectal), you must have already tried at least one prior treatment that didn't work or stopped working.
- You have a good performance status (able to carry out daily activities) as measured by an ECOG score of 0 or 1.
- Your tumor can be measured on scans (like CT or MRI) using standard criteria.
- You are willing to have tumor biopsies before and during treatment if you are in certain parts of the study (Parts A1 and A2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests the safety and early signs of benefit from CJRB-101 when combined with pembrolizumab (Keytruda) in people with advanced or metastatic lung, head and neck, or melanoma cancer. It may help some participants, but the main goal is to see how safe the combination is and whether it can control cancer.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This early-phase study tests a new treatment in people with advanced (locally advanced or metastatic) solid tumors that have worsened or cannot be treated with standard therapies. It may help shrink tumors or slow growth, and it also helps doctors learn the safest way to use the medicine.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.